Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V3ZA
|
||||
| Former ID |
DAP000078
|
||||
| Drug Name |
Dihydroergotamine
|
||||
| Synonyms |
Agit; Angionorm; DIHYDROERGOTOXINE; Dehydroergotamine; Dergotamine; Diergo; Dihidroergotamina; Dihydergot; Dihydroergotaminum; Dihydroergotoxin; Diidroergotamina; Dirgotarl; Endophleban; Ergomimet; Ergont; Ergotonin; Ikaran; Migranal; Morena; Neomigran; Orstanorm; Seglor; Tonopres; Verladyn; DET MS; Dihydroergotamine methanesulfonate; Diidroergotamina [DCIT]; Ergoloid dihydroergotoxine; Co-Dergocrine; DHE-45; Dihidroergotamina [INN-Spanish]; Dihydroergotamine (INN); Dihydroergotaminum [INN-Latin]; ErgoloidMesylates (dihydroergotoxine); Ergot Alkaloids, Hydrogenated; Migranal (TN); Neomigran (TN); (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; 9,10-Dihydroergotamine; 9,10-dihydro-ergotamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Migraine headaches [ICD9: 346; ICD10:G43] | Approved | [1], [2] | ||
| Therapeutic Class |
Antimigraine Agents
|
||||
| Company |
Pfizer Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C33H37N5O5
|
||||
| InChI |
InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
|
||||
| InChIKey |
LUZRJRNZXALNLM-JGRZULCMSA-N
|
||||
| CAS Number |
CAS 6190-39-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10000, 7979087, 8157604, 11335767, 11361006, 11363951, 11366513, 11369075, 11371529, 11374714, 11377237, 11461978, 11484971, 11489004, 11490211, 11492773, 11494871, 14788984, 14935810, 29229015, 46507711, 47291112, 47885391, 48110437, 48334472, 49963030, 49965612, 50153282, 57326281, 85789540, 90341683, 93166278, 96024534, 99313633, 103684622, 103905875, 104137088, 104171355, 104323551, 119501400, 124749650, 124883197, 124883198, 126688923, 127323995, 127323996, 127323997, 127323998, 127323999, 127324000
|
||||
| SuperDrug ATC ID |
N02CA01
|
||||
| SuperDrug CAS ID |
cas=000511126
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Migraine: a pharmacologic review with newer options and delivery modalities. Neurology. 1994 May;44(5 Suppl 3):S13-7. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 121). | ||||
| REF 3 | Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. Epub 2008 Jul 15. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.